Compare · NVS vs VYNE
NVS vs VYNE
Side-by-side comparison of Novartis AG (NVS) and VYNE Therapeutics Inc. (VYNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and VYNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $287.12B.
- NVS has been more active in the news (6 items in the past 4 weeks vs 5 for VYNE).
- NVS has more recent analyst coverage (25 ratings vs 3 for VYNE).
- Company
- Novartis AG
- VYNE Therapeutics Inc.
- Price
- -
- -
- Market cap
- $287.12B
- -
- 1M return
- -3.71%
- -
- 1Y return
- +18.20%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 3
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
Latest VYNE
- Chief Development Officer Payton Lori was granted 99,827 stock options (SEC Form 4)
- Chief Operating Officer Alford Rachael was granted 89,844 stock options (SEC Form 4)
- Chief Executive Officer Frey Rebecca was granted 465,857 stock options (SEC Form 4)
- Chief Medical Officer Ryder Steven was granted 113,137 stock options (SEC Form 4)
- Chief Financial Officer Zeronda Tyler was granted 156,115 stock options (SEC Form 4)
- VYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by VYNE Therapeutics Inc.
- SEC Form 424B5 filed by VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form EFFECT filed by VYNE Therapeutics Inc.